ArticleInvestigational new drugs2016

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.

Lee S Rosen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.